Prostate Cancer and Prostatic Diseases

Papers
(The H4-Index of Prostate Cancer and Prostatic Diseases is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
The imperative for clinical trial diversity: Perspectives in the context of prostate-specific membrane antigen-targeted imaging79
Best of 2022 in prostate cancer and prostatic diseases77
A randomized controlled trial evaluating low-intensity shockwave therapy for treatment of persistent storage symptoms following transurethral surgery for benign prostatic obstruction73
Will generalist medical artificial intelligence be the future path for health-related natural language processing models?62
Reply to RE: Should LHRH therapy be continued in patients receiving Abiraterone Acetate?55
Germline alterations among Hispanic men with prostate cancer52
Perioperative outcomes of HoLEP, ThuLEP, and TURP in patients with prostate cancer: results from the GRAND study49
Social determinants of health: does socioeconomic status affect access to staging imaging for men with prostate cancer48
Concerns regarding prostate cancer screening guidelines in minority populations45
Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs)41
The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches37
Integrating clinical and public health perspectives on statin use and prostate cancer risk: addressing key limitations and future directions35
New BPH therapy classification: what really FITs?35
Hypofractionated radiotherapy in elderly patients (≥75 years) affected by localized prostate cancer: a multicenter retrospective analysis from the IPOPROMISE study35
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or andro34
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer34
Sexual outcomes in men who have sex with men who underwent radical prostatectomy34
Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States32
Prognostic value of a baseline prognostic nutritional index for patients with prostate cancer: a systematic review and meta-analysis32
More evidence that physical activity is beneficial for prostate cancer32
Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations30
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis30
Perceived patient burden and acceptability of MRI in comparison to PSA and ultrasound: results from the IP1-PROSTAGRAM study29
Concurrent prognostic utility of lymph node count and lymph node density for men with pathological node-positive prostate cancer28
Correction: Application of next-generation imaging in biochemically recurrent prostate cancer28
Incidence of prostate cancer in transgender women in the US: a large database analysis27
Prostate cancer and podcasts: an analysis and assessment of the quality of information about prostate cancer available on podcasts27
0.059977054595947